DaelmanLMaitrotAMaaroufA. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler. 2012Nov;18(11):1647–1649
2.
BloomgrenGRichmanSHotermansC. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med2012; 366: 1870–1880.
3.
KhatriBOManSGiovannoniG. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology2009; 72: 402–409.
4.
O’ConnorPWGoodmanAKapposL. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology2011; 76: 1858–1865.
5.
RispensTVennegoorAWolbinkGJ. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler2012; 18: 899–901.
6.
IferganIKebirHAlvarezJI. Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on alpha4 integrin. Brain2011; 134: 3560–3577.
